Open Access
Open access
volume 8 issue 5

Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma

Yang Li 1
Ping Hu 1
XIALI WANG 2
Hou Xu 3
Feng Zhen Liu 4
Xiaohong Jiang 1, 5
1
 
Zhong Yuan Academy of Biological Medicine, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, China
2
 
Clinical Laboratory, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, China
3
 
Department of Hepatobiliary Surgery, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, China
Publication typeJournal Article
Publication date2021-08-09
scimago Q1
wos Q1
SJR1.216
CiteScore9.6
Impact factor8.1
ISSN20563418, 20563426
PubMed ID:  34457350
Biomaterials
Abstract

Photothermal therapy (PTT) has emerged as a promising cancer therapeutic method. In this study, Arg-Gly-Asp (RGD) peptide-conjugated polydopamine-coated gold nanostars (Au@PDA-RGD NPs) were prepared for targeting PTT of hepatocellular carcinoma (HCC). A polydopamine (PDA) shell was coated on the surface of gold nanostars by the oxidative self-polymerization of dopamine (termed as Au@PDA NPs). Au@PDA NPs were further functionalized with polyethylene glycol and RGD peptide to improve biocompatibility as well as selectivity toward the HCC cells. Au@PDA-RGD NPs showed an intense absorption at 822 nm, which makes them suitable for near-infrared-excited PTT. Our results indicated that the Au@PDA-RGD NPs were effective for the PTT therapy of the αVβ3 integrin receptor-overexpressed HepG2 cells in vitro. Further antitumor mechanism studies showed that the Au@PDA-RGD NPs-based PTT induced human liver cancer cells death via the mitochondrial–lysosomal and autophagy pathways. In vivo experiments showed that Au@PDA-RGD NPs had excellent tumor treatment efficiency and negligible side effects. Thus, our study showed that Au@PDA-RGD NPs could offer an excellent nanoplatform for PTT of HCC.

Found 
Found 

Top-30

Journals

1
2
Regenerative Biomaterials
2 publications, 6.45%
Nanomaterials
2 publications, 6.45%
Biomedicine and Pharmacotherapy
2 publications, 6.45%
Journal of Materials Chemistry B
2 publications, 6.45%
Nano Convergence
1 publication, 3.23%
Frontiers in Cell and Developmental Biology
1 publication, 3.23%
International Journal of Molecular Sciences
1 publication, 3.23%
Bioengineering & Translational Medicine
1 publication, 3.23%
Materials Today Communications
1 publication, 3.23%
Journal of Biomedical Materials Research - Part B Applied Biomaterials
1 publication, 3.23%
Advanced Functional Materials
1 publication, 3.23%
Micromachines
1 publication, 3.23%
ACS applied materials & interfaces
1 publication, 3.23%
World Journal of Hepatology
1 publication, 3.23%
Journal of Biomaterials Science, Polymer Edition
1 publication, 3.23%
International Journal of Nanomedicine
1 publication, 3.23%
ACS Applied Nano Materials
1 publication, 3.23%
Journal of Nanobiotechnology
1 publication, 3.23%
Clinics and Research in Hepatology and Gastroenterology
1 publication, 3.23%
Clinical and Experimental Medicine
1 publication, 3.23%
Applied Surface Science
1 publication, 3.23%
Bioorganic Chemistry
1 publication, 3.23%
ACS Applied Polymer Materials
1 publication, 3.23%
Russian Chemical Reviews
1 publication, 3.23%
Advanced Materials
1 publication, 3.23%
Discover Applied Sciences
1 publication, 3.23%
Advanced Science
1 publication, 3.23%
1
2

Publishers

1
2
3
4
5
6
Elsevier
6 publications, 19.35%
Wiley
5 publications, 16.13%
Springer Nature
4 publications, 12.9%
MDPI
4 publications, 12.9%
American Chemical Society (ACS)
3 publications, 9.68%
Oxford University Press
2 publications, 6.45%
Taylor & Francis
2 publications, 6.45%
Royal Society of Chemistry (RSC)
2 publications, 6.45%
Frontiers Media S.A.
1 publication, 3.23%
Baishideng Publishing Group
1 publication, 3.23%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
1
2
3
4
5
6
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
31
Share
Cite this
GOST |
Cite this
GOST Copy
Li Y. et al. Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma // Regenerative Biomaterials. 2021. Vol. 8. No. 5.
GOST all authors (up to 50) Copy
Li Y., Hu P., WANG X., Xu H., Liu F. Z., Jiang X. Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma // Regenerative Biomaterials. 2021. Vol. 8. No. 5.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1093/rb/rbab046
UR - https://doi.org/10.1093/rb/rbab046
TI - Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma
T2 - Regenerative Biomaterials
AU - Li, Yang
AU - Hu, Ping
AU - WANG, XIALI
AU - Xu, Hou
AU - Liu, Feng Zhen
AU - Jiang, Xiaohong
PY - 2021
DA - 2021/08/09
PB - Oxford University Press
IS - 5
VL - 8
PMID - 34457350
SN - 2056-3418
SN - 2056-3426
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Li,
author = {Yang Li and Ping Hu and XIALI WANG and Hou Xu and Feng Zhen Liu and Xiaohong Jiang},
title = {Integrin αvβ3-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma},
journal = {Regenerative Biomaterials},
year = {2021},
volume = {8},
publisher = {Oxford University Press},
month = {aug},
url = {https://doi.org/10.1093/rb/rbab046},
number = {5},
doi = {10.1093/rb/rbab046}
}